TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

Benzinga_recent_news10-08

TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology. The...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2573221069?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/08/Pipette-Adding-Fluid-To-One-Of-Several-T.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-10-08 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573221069","market":"us","top_or_hot":-1,"title":"TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout","media":"Benzinga_recent_news","content":"<div>\n<p>TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.\nThe...</p>\n\n<a href=\"https://www.benzinga.com/m-a/25/10/48102558/transcode-makes-bold-bet-on-melanoma-vaccine-with-polynoma-buyout\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-08 22:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/m-a/25/10/48102558/transcode-makes-bold-bet-on-melanoma-vaccine-with-polynoma-buyout><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.\nThe...</p>\n\n<a href=\"https://www.benzinga.com/m-a/25/10/48102558/transcode-makes-bold-bet-on-melanoma-vaccine-with-polynoma-buyout\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.benzinga.com/m-a/25/10/48102558/transcode-makes-bold-bet-on-melanoma-vaccine-with-polynoma-buyout","article_id":"2573221069","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/08/Pipette-Adding-Fluid-To-One-Of-Several-T.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/m-a/25/10/48102558/transcode-makes-bold-bet-on-melanoma-vaccine-with-polynoma-buyout","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2573221069","pubTimestamp":1759934880,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"TransCode Therapeutics Inc. (NASDAQ: RNAZ) to acquire Polynoma LLC and receive $25 million investment from CK Life Sciences.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","RNAZ":"TransCode Therapeutics  Inc.","BK4139":"生物科技","BK4161":"工业机械","CVR":"芝加哥机械"},"translate_title":"TransCode通过收购Polynoma大胆押注黑色素瘤疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAZ":1,"CVR":1},"content_text":"TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.\nThe acquisition adds Polynoma's lead candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine being developed for the adjuvant treatment of stage IIB and IIC melanoma, to TransCode's development pipeline.\nUnder the terms of the definitive agreement, TransCode Therapeutics will issue to the sole stockholder of Polynoma LLC, an indirect wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (OTC:CKLSF), a total of 83,285 shares of common stock and 1,152.9568 shares of non-voting Series A convertible preferred stock at a 1:10,000 ratio.\nAlso Read: Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket\nAlongside its planned acquisition of Polynoma LLC, TransCode Therapeutics announced a $25 million strategic investment from CK Life Sciences.\nCK Life Sciences’ subsidiary purchased 223.7337 shares of non-voting Series B preferred stock, convertible into common shares at a 1:10,000 ratio. The investment includes $20 million in cash and a $5 million promissory note.\nThe funding will primarily support the advancement of TTX-MC138, TransCode's lead microRNA-based therapeutic, into a Phase 2 clinical trial.\nBoth transactions are expected to close on October 8, 2025, resulting in CK Life Sciences holding about 91% of TransCode's fully diluted equity and pre-acquisition stockholders retaining roughly 9%, including transaction fees. The combined transactions imply a fully diluted equity value of approximately $165 million.\nTransCode Therapeutics said up to $95 million in additional payments may be made to the CK Life Sciences subsidiary based on the achievement of clinical, regulatory, and commercial milestones for seviprotimut-L.\nIn addition, the company's stockholders of record as of October 20, 2025, will receive a non-transferable contingent value right (CVR), entitling them to potential proceeds from future upfront, development, or regulatory milestone payments stemming from any corporate partnering deal involving TTX-MC138.\nTransCode Therapeutics had cash of $7.37 million as of June 30, 2025.\nDr.  Philippe Calais stated, “I am very honored to deepen my commitment and lead TransCode’s transformation into a one-of-a-kind leading oncology company at this critical time. We are grateful for CK Life Sciences’ investment and their support of our miRNA candidate, TTX-MC138, as we now have the funding in place to fully execute our upcoming TTX-MC138 Phase 2. \"\nThe company announced that Philippe Calais, PharmD, PhD, has been appointed Chief Executive Officer while continuing to serve as Chairman of the Board. Calais has stepped down from his roles on the Board's Audit and Compensation Committees.\nTom Fitzgerald, who had been serving as Interim CEO, will step down from that role but remain Chief Financial Officer and a member of the Board of Directors.\nPrice Action: RNAZ shares were trading higher by 39.44% to $17.04 at last check Wednesday.\nRead Next:\nPhoto by motorolka via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2573221069","isCrawlerRequest":true}